W

hen it comes to developing cancer treatments, the pharmaceutical industry has long prioritized drugs for conditions that disproportionately turn up in patients in the West.

That has meant less attention to certain types of cancer, like those of the stomach and esophagus, that disproportionately affect patients in China.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.